GeneTherapyLive’s Weekly Rewind – February 11, 2022

Article

Review top news and interview highlights from the week ending February 11, 2022.

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Assessing EtranaDez for Hemophilia B in HOPE-B: Wolfgang Miesbach, MD, PhD

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study. He gave an overview of the study, discussing the positive data and outcomes.

2. Stargardt Disease Gene Therapy IND Cleared to Proceed

Nanoscope Therapeutics has received approval from the FDA for its investigational new drug application for MCO-010, a gene therapy for the potential treatment of Stargardt disease, a type of macular degeneration.

3. The Importance of Collaboration in Developing Next Generation Cell Therapies

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies as well as future collaborations and research that Medigene is pursuing.

4. CAR T-Cell Therapy Efficacious at 10 Years in Chronic Lymphocytic Leukemia

New findings, from a recent study evaluating 10-year follow-up of patients with complete responses to chronic lymphocytic leukemia (CLL) chimeric antigen receptor (CAR) T-cell treatment, have elucidated the long-term role of CD19+ CAR T-cells in the body.

5. Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors and developing personalized immunotherapies for solid tumors.

Recent Videos
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Related Content
© 2024 MJH Life Sciences

All rights reserved.